Puma (PBYI) Q2 Revenue Rises 11%

Puma Biotechnology (PBYI) reported strong Q2 2025 results, with non-GAAP EPS of $0.15 beating estimates of $0.09 and revenue of $52.4 million, up 11.3% year-over-year and slightly above expectations. The company returned to GAAP profitability with a net income of $5.9 million, driven by robust NERLYNX product sales growth and disciplined expense management, including a 28% reduction in SG&A. Management reiterated full-year guidance, highlighting continued reliance on NERLYNX while advancing the alisertib pipeline, with Phase II data expected in Q4 2025, and pursuing diversification beyond its core product.

Analysis

Puma Biotechnology reported strong Q2 2025 results, outperforming market expectations with non-GAAP EPS of $0.15 against a $0.09 consensus and revenue of $52.4 million, an 11.3% year-over-year increase. The company achieved a significant turnaround, posting a GAAP net income of $5.9 million compared to a $4.5 million loss in the prior-year quarter. This profitability was driven by a combination of solid commercial execution for its sole product, NERLYNX, whose net product revenue grew 10.8% to $49.2 million, and substantial cost discipline. Notably, SG&A expenses fell 28% year-over-year, a reduction attributed primarily to the non-recurrence of significant legal fees, suggesting this level of margin benefit may not be sustainable. In contrast, R&D expenses increased 14% to $15.5 million to fund the advancement of its key pipeline asset, alisertib. While management reiterated full-year guidance, the Q3 revenue forecast of $48 million to $51 million indicates a potential sequential slowdown. The company remains a single-product story, with future growth heavily dependent on the successful development of alisertib, which has Phase II data expected in Q4 2025, and overcoming royalty revenue headwinds stemming from regulatory changes in China.

Key Decisions for Investors

• Investors should recognize that the strong quarterly performance was driven by solid NERLYNX execution and a significant, non-recurring reduction in legal expenses, which temporarily enhanced the margin profile.
• The primary forward-looking catalyst is the Phase II clinical data for alisertib, expected in Q4 2025, which is critical for de-risking the pipeline and providing a path to revenue diversification.
• Monitor revenue trajectory against the reiterated full-year guidance, paying close attention to the softer Q3 forecast, persistent royalty revenue headwinds from China, and the slight increase in gross-to-net adjustments.